Voyager Therapeutics

Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production.
The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.
Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.

Type

Public

HQ

Cambridge, US

Founded

2014

Employees

52 (est)

Voyager Therapeutics was founded in 2014 and is headquartered in Cambridge, US

Key People at Voyager Therapeutics

Jeff Goater

Vice President of Business Development

Jim Geraghty

Interim Chief Business Officer

Guangping Gao

Founder

Mark Kay

Founder

Phillip D. Zamore

Founder

Krystof Bankiewicz

Founder

Voyager Therapeutics Locations

Cambridge, US

Voyager Therapeutics Metrics

Voyager Therapeutics Summary

Market capitalization

$367 M

Closing share price

$14

Voyager Therapeutics's latest market capitalization is $367 M.

Voyager Therapeutics Market Value History

46% of current employees of Voyager Therapeutics are female and 54% are male.